Showing posts with label abstract. Show all posts
Showing posts with label abstract. Show all posts

Sunday, May 10, 2026

#Detection and #isolation of #H5N1 clade 2.3.4.4b #influenza virus from #ticks recovered from a naturally infected slender-billed #gull

 


Abstract

Laridae birds, such as gulls, are known reservoirs of H13 and H16 low pathogenicity avian influenza virus (LPAIV) subtypes. However, during the recent outbreaks linked to the reemergence of high pathogenicity avian influenza virus (HPAIV) H5N1 clade 2.3.4.4b of the Goose/Guangdong lineage, European populations of Laridae birds suffered significant losses. HPAI cases were reported not only along the coastlines but also inland areas, particularly in France and Central Europe. During a diagnostic investigation of a group of Laridae birds, part of a HPAIV outbreak reported in the South of France in 2023, larval stages of Ornithodoros maritimus, a nidicolous soft tick parasitizing seabirds, were recovered from a slender-billed gull (Chroicocephalus genei). Affected birds exhibited gross and histopathological lesions consistent with systemic HPAIV infection. Immunohistochemistry revealed marked neurotropism, oculotropism and multicentric epitheliotropism. Viral isolation and sequencing analysis confirmed the presence of HPAIV H5N1 clade 2.3.4.4b in both the gull and ectoparasites, showing from 99.64% to 100% nucleotide identity across five of eight RNA segments. While additional research is needed to properly assess the vector competence of O. maritimus for HPAIV, ticks may represent an interesting non-invasive surveillance tool for these viruses. This is the first time a HPAIV has been successfully isolated from tick larvae. These findings represent a first step toward understanding the potential role played by ticks in the spread of avian influenza viruses within marine bird colonies and among other ecosystems, considering the occurrence of specific behavioral traits, such as kleptoparasitim and the position of gulls at the interface between wild and domestic species.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

Agence Nationale de la Recherche, https://ror.org/00rbzpz17

INRAe Animal Health Department

Source: 

____

Saturday, May 9, 2026

#Genetic and #biological characterization of #H9N2 avian #influenza viruses isolated from #swine in #China

 


Abstract

Background

H9N2 avian influenza virus (AIV) has been circulating in poultry in China for decades and are undergoing adaptation to mammals, posing potential pandemic risks. To investigate the prevalence of H9N2 AIVs in swine, we conducted surveillance in Shandong Province from 2021 to 2023.

Results

Two H9N2 influenza virus strains, A/swine/Shandong/417/2021(Sw/SD/417/21) and A/swine/Shandong/662/2022 (Sw/SD/662/22), were successfully isolated from swine and genetically characterized. Phylogenetic analyses showed that both isolates were reassortants containing gene segments from multiple H9N2 AIV lineages and closely related to currently circulating H9N2 AIV. Key molecular marker analysis revealed that both isolates carried mammalian-adaptive residues in the HA receptor-binding sites (183 N, 190 V, 226 L), a novel HA cleavage site variant (PSKSSRGL), PB2 mutations (A588V, E627V), and the M2 S31N substitution, suggesting potential adaptation to mammalian hosts and resistance to adamantane antivirals. Mice infection experiments demonstrated efficient viral replication in the respiratory tract, particularly in the lungs, but only mild histopathological changes were observed, with no significant weight loss or mortality, indicating low pathogenicity in mice. Serological surveillance of 3,172 swine serum samples showed a low prevalence of H9N2 influenza virus infection (0.44%), with positive samples sporadically distributed across regions and years.

Conclusion

In summary, although H9N2 AIV infection in swine is rare and generally mild, the presence of mammalian-adaptive markers and reassortant genomes highlights the potential risk of cross-species transmission and subclinical adaptation. Continuous avian–swine–human influenza surveillance is therefore essential to mitigate the potential threat posed by H9N2 AIV.

Source: 


Link: https://link.springer.com/article/10.1186/s12917-026-05501-z

____

#Coronavirus Disease Research #References (by AMEDEO, May 9 '26)

 


    Clin Infect Dis

  1. BOZIO CH, Patel M, Reed C, Garg S, et al
    Challenges in defining severe influenza with implications for measuring and communicating influenza vaccine effects.
    Clin Infect Dis. 2026 May 7:ciag304. doi: 10.1093.
    PubMed         Abstract available


    Int J Infect Dis

  2. HIBINO M, Shintani A, Murayama H, Morikawa N, et al
    Impact of Early Oral Antiviral Use for Outpatients With COVID-19 on Healthcare Utilization and Recovery (ANCHOR-02).
    Int J Infect Dis. 2026 May 2:108754. doi: 10.1016/j.ijid.2026.108754.
    PubMed         Abstract available

  3. KURITA J, Mukasa K, Kawana Y, Kaneko M, et al
    Cooperative surveillance association and incidence of infectious diseases in Japanese nursery schools.
    Int J Infect Dis. 2026 Apr 30:108757. doi: 10.1016/j.ijid.2026.108757.
    PubMed         Abstract available

  4. LEWIS L, Mohammed D, Evans L, Patterson B, et al
    COVID-19 Hospitalisations in women of childbearing age and children during the Omicron period, January 2023 to September 2024.
    Int J Infect Dis. 2026 Apr 30:108746. doi: 10.1016/j.ijid.2026.108746.
    PubMed         Abstract available


    J Med Virol

  5. ANINAGYEI E, Ayivor-Djanie R, Boatey CA, Mateen AA, et al
    High SARS-CoV-2 Antibody Seroprevalence Amid COVID-19 Vaccine Hesitancy Among Unvaccinated Adults in Ghana.
    J Med Virol. 2026;98:e70962.
    PubMed         Abstract available

  6. STONE S, Elsharkawy A, Patterson LD, Natekar JP, et al
    A Novel Humanized Lethal Mouse Model of SARS-CoV-2-Associated Disease.
    J Med Virol. 2026;98:e70959.
    PubMed         Abstract available


    J Virol

  7. SUOMALAINEN M, Haenseler W, Kolibius J, Pluckthun A, et al
    Transcriptional transactivation turns human iPSC-derived macrophages into an adenovirus-producing cell state.
    J Virol. 2026 May 4:e0039226. doi: 10.1128/jvi.00392.
    PubMed         Abstract available

  8. ZHANG L, Hoffmann M, Pohlmann S
    Lock out: targeting TMPRSS2 to block influenza and coronaviruses.
    J Virol. 2026 May 4:e0080725. doi: 10.1128/jvi.00807.
    PubMed         Abstract available


    Lancet Infect Dis

  9. RITCHIE AJ, Hassan O, Urasa N, Apanga PA, et al
    Safety and immunogenicity of a single-dose adenovirus-vectored rabies vaccine over 1 year in adults and children in Tanzania: interim data from an ongoing, partly randomised, controlled, phase 1b/2 trial.
    Lancet Infect Dis. 2026 Apr 28:S1473-3099(26)00071.
    PubMed         Abstract available


    Nature

  10. BAO Z, Liu Z, Zhang Z, Wang X, et al
    Steric hindrance of antibody binding in an Omicron spike fusion intermediate.
    Nature. 2026 May 6. doi: 10.1038/s41586-026-10462.
    PubMed         Abstract available


    Science

  11. COHEN J
    Arrest of Fauci aide for records violations decried as political.
    Science. 2026;392:565-566.
    PubMed         Abstract available

  12. COHEN J
    After pulling vaccine study, CDC leader calls for new journal.
    Science. 2026;392:564-565.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, May 9 '26)

 


    Antimicrob Agents Chemother

  1. SULEA T, Stuible M, Moreno M, Pelletier A, et al
    Multifunctional ACE2-nanobody fusion design for pan-specific neutralization and cardiovascular protection in SARS coronavirus infection.
    Antimicrob Agents Chemother. 2026;70:e0002426.
    PubMed         Abstract available


    Antiviral Res

  2. CHIBA S, Kiso M, Yamayoshi S, Uraki R, et al
    Niclosamide inhibits the replication of highly pathogenic avian influenza A (H5Nx) viruses and antiviral-resistant mutants.
    Antiviral Res. 2026;251:106421.
    PubMed         Abstract available


    Cell

  3. HAVENS JL, Kosakovsky Pond SL, Zehr JD, Pekar JE, et al
    Dynamics of natural selection preceding human viral epidemics and pandemics.
    Cell. 2026;189:2762-2775.
    PubMed         Abstract available


    Epidemiol Infect

  4. MORTON LC, Forshey BM, Klinkhammer KE, Romaner A, et al
    Local genomic epidemiology investigations of SARS-CoV-2 during the early pandemic response: A global systematic review.
    Epidemiol Infect. 2026;154:e56.
    PubMed         Abstract available


    J Gen Virol

  5. SANTOS IA, Grosche VR, Oliveira LDS, Guarda PHS, et al
    Copper(II) benzyloxychalcone analogues as new potential metallodrugs against SARS-CoV-2 replication.
    J Gen Virol. 2026;107:002245.
    PubMed         Abstract available

  6. ISLAM MT, Pillatzki A, Webb B, Ramamoorthy S, et al
    Infectivity of recombinant Torque teno sus virus 1 in pigs coinfected with swine influenza virus.
    J Gen Virol. 2026;107:002264.
    PubMed         Abstract available

  7. SCHAFERS J, Warren CJ, Yang J, Zhang J, et al
    Stability of influenza viruses in the milk of cows and sheep.
    J Gen Virol. 2026;107:002257.
    PubMed         Abstract available


    J Infect

  8. BEHARIER O, Guedalia J, Sehtman-Shachar DR, Kerem L, et al
    Maternal SARS-CoV-2 Infection and Early Child Growth and Development: A Nationwide Cohort Study.
    J Infect. 2026 Apr 17:106749. doi: 10.1016/j.jinf.2026.106749.
    PubMed         Abstract available

  9. PEREZ-MAZZALI M, Perez-Cozar F, Cal-Sabater P, Rybakowska P, et al
    Persistent T cell phenotypic alterations and early innate immune dysregulation as potential biomarkers of Long COVID.
    J Infect. 2026 Mar 17:106731. doi: 10.1016/j.jinf.2026.106731.
    PubMed         Abstract available


    J Virol

  10. ZHANG L, Hoffmann M, Pohlmann S
    Lock out: targeting TMPRSS2 to block influenza and coronaviruses.
    J Virol. 2026 May 4:e0080725. doi: 10.1128/jvi.00807.
    PubMed         Abstract available


    MMWR Morb Mortal Wkly Rep

  11. KIBIGER L, Oltean HN, Leitz L, Krause E, et al
    Fatal Human Case of Highly Pathogenic Avian Influenza A(H5N5) in a Backyard Flock Owner - Washington, November 2025.
    MMWR Morb Mortal Wkly Rep. 2026;75:221-225.
    PubMed         Abstract available

  12. VAUGHAN A, Joyce A, Traub E, Jae M, et al
    Serologic Evidence of Highly Pathogenic Avian Influenza A(H5N1) Virus Infection in a Veterinary Professional Exposed to an Infected Domestic Cat - Los Angeles County, California, December 2024-January 2025.
    MMWR Morb Mortal Wkly Rep. 2026;75:215-220.
    PubMed         Abstract available


    N Engl J Med

  13. LITE TL, Goya S, Davis ML, Morris AE, et al
    Human Infection with Highly Pathogenic Avian Influenza A(H5N5) Virus.
    N Engl J Med. 2026 May 7. doi: 10.1056/NEJMc2518178.
    PubMed        

  14. LEROUX-ROELS I, Huang G, Ferguson M, Kohli A, et al
    Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults.
    N Engl J Med. 2026;394:1803-1813.
    PubMed         Abstract available


    PLoS Biol

  15. CAMPBELL AJ, Shephard M, Paulos AP, Pauly MD, et al
    Surveillance on California dairy farms reveals multiple possible sources of H5N1 influenza virus transmission.
    PLoS Biol. 2026;24:e3003761.
    PubMed         Abstract available


    PLoS Comput Biol

  16. MCTIERNAN J, Zhang Y, Li S, Kuhlman TE, et al
    Clustering of SARS-CoV-2 membrane proteins in lipid bilayer membranes.
    PLoS Comput Biol. 2026;22:e1014229.
    PubMed         Abstract available


    PLoS Med

  17. O'HAGAN A, Pechey R, Forde H, Bandy L, et al
    Adherence to voluntary UK sugar, salt, and calorie reduction targets in the highest-grossing restaurant chains: A cross-sectional study.
    PLoS Med. 2026;23:e1004681.
    PubMed         Abstract available

  18. KRUK ME, Kapoor NR, Arsenault C, Carai S, et al
    Health system use and experience among people with poor mental health: A cross-sectional analysis of the People's Voice Survey in 18 countries.
    PLoS Med. 2026;23:e1004745.
    PubMed         Abstract available


    PLoS One

  19. DO NASCIMENTO AI, Dos Santos Conrado D, Mareto LK, de Azevedo MV, et al
    Age and vaccine information sources drive vaccine hesitancy: A household survey in Central-Western Brazil.
    PLoS One. 2026;21:e0348412.
    PubMed         Abstract available

  20. SIEBELS K, Ogden NH, Turgeon P, Lapeyre J, et al
    The impact of non-pharmaceutical interventions on the socio-economic and demographic determinants of COVID-19 incidence: A spatial analysis of the pandemic in Toronto, Canada.
    PLoS One. 2026;21:e0347649.
    PubMed         Abstract available

  21. CHU L, Hollar TL, Klimas N, Bertolli J, et al
    Facilitators of and barriers to participation in Long COVID research: A qualitative analysis.
    PLoS One. 2026;21:e0346007.
    PubMed         Abstract available

  22. WEATHERALD J, Wen C, Sharpe H, Leung WM, et al
    Impact of the COVID-19 pandemic on sex-related disparities in cystic fibrosis healthcare utilization and outcomes: A population study.
    PLoS One. 2026;21:e0345009.
    PubMed         Abstract available

  23. BIR C, Jung J, Widmar NO
    Understanding why people value working from home or hybrid workplace flexibility a study of preferences during the COVID-19 pandemic.
    PLoS One. 2026;21:e0348206.
    PubMed         Abstract available

  24. KABATA Y, Terauchi R, Nakano T
    Nationwide trends and regional variation in intravitreal injections and anti-VEGF agent use in Japan from 2017 to 2022: An analysis of the NDB Open Data.
    PLoS One. 2026;21:e0348087.
    PubMed         Abstract available

  25. PARK JH, Lee MT, Jung SY, Choi ST, et al
    Association between coronavirus disease 2019 and new-onset autoimmune diseases during the early phase of the pandemic.
    PLoS One. 2026;21:e0347872.
    PubMed         Abstract available

  26. TORREJON-GUIRADO MC, Baena-Jimenez MA, Lima-Serrano M
    Association between cannabis use and result of COVID-19 testing among scholarised adolescents in Andalusia: A cross-sectional study.
    PLoS One. 2026;21:e0347098.
    PubMed         Abstract available

  27. COSKUNER AKTAS S
    Work-family conflict in times of crisis: The moderating roles of self-efficacy and time-based spousal support during pandemic-induced remote work.
    PLoS One. 2026;21:e0348368.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  28. WAN Z, Yu L, Yang Z, Luo S, et al
    Stag2-mediated chromatin dynamics regulates antibody class switch recombination.
    Proc Natl Acad Sci U S A. 2026;123:e2536391123.
    PubMed         Abstract available


    Vaccine

  29. BEOGO I, Muray M, Kibret TC, Xu Y, et al
    Between racism and rumors: understanding vaccine mistrust among older racially diverse adults in Canada.
    Vaccine. 2026;82:128611.
    PubMed         Abstract available

  30. CONNER TL, Goguet E, Haines-Hull H, Segard A, et al
    mRNA COVID-19 vaccination induces minimal IgA in saliva in the absence of prior clinical or subclinical infection.
    Vaccine. 2026;82:128612.
    PubMed         Abstract available

  31. SARNAIK AY, Khan ZU, Rajeswaran T, Majoe A, et al
    The role of misinformation in COVID-19 vaccine hesitancy in low- & middle-income countries.
    Vaccine. 2026;82:128595.
    PubMed         Abstract available

  32. PAUL KK, Torres M, Shih STF, Gray RT, et al
    Estimating the cost-effectiveness of respiratory syncytial virus (RSV) vaccination program for older Australian adults.
    Vaccine. 2026;82:128591.
    PubMed         Abstract available

  33. GULATI RR, Yaqub F, Goodman AL
    Enhancing uptake of respiratory vaccinations in asthma and chronic obstructive pulmonary disease (COPD) patients: a systematic review.
    Vaccine. 2026;81:128560.
    PubMed         Abstract available

  34. WU JD, Meng H, Guo XL, Liu L, et al
    The immune response of the mRNA vaccine CS-2034 as a heterologous booster before and after breakthrough infection: A follow-up study.
    Vaccine. 2026;81:128575.
    PubMed         Abstract available

  35. HIRAKAWA T, Yamada G, Tokiya M, Furukawa T, et al
    Impact of pre-vaccination active vitamin D levels on COVID-19 mRNA vaccine-induced immunity in a Japanese cohort.
    Vaccine. 2026;81:128576.
    PubMed         Abstract available

  36. KONLAN M, Bhandari R, Owusu SA, Kubio C, et al
    The effect of the COVID-19 pandemic on routine childhood immunization coverage and dropout: A community-based cross-sectional study in the Tamale Metropolis, Ghana.
    Vaccine. 2026;81:128584.
    PubMed         Abstract available

  37. REYNALDI A, Lee WS, Selva KJ, Audsley J, et al
    Immune responses associated with protection from SARS-CoV-2 infection.
    Vaccine. 2026;81:128579.
    PubMed         Abstract available

  38. HIGGINS RA, Mazarakis N, Sun C, Toh ZQ, et al
    Effect of time-of-day vaccination on the antibody response to mRNA and protein COVID-19 vaccine in adults.
    Vaccine. 2026;81:128574.
    PubMed         Abstract available

  39. GASHEMA P, Iradukunda PG, Rudacogora JC, Siddig EE, et al
    Unlocking Africa's vaccine Independence: The critical role of technology transfer and intellectual property.
    Vaccine. 2026;81:128573.
    PubMed         Abstract available

  40. HAVERKATE MR, van de Kassteele J, van den Hof S, Sanders JG, et al
    The effect of pre-booked appointments on COVID-19 vaccine uptake among previously vaccinated older adults during the 2023 autumn campaign in the Netherlands: a regression discontinuity analysis.
    Vaccine. 2026;81:128565.
    PubMed         Abstract available


    Virology

  41. ZHU M, Wang R, Li X, Zhou H, et al
    Canine influenza virus at the human-animal interface: origins, adaptive evolution, and implications for public health.
    Virology. 2026;621:110943.
    PubMed         Abstract available

  42. LIU C, Yuan X
    Respiratory viruses as key drivers of pulmonary fibrosis: integrated pathways from barrier injury to immune-fibrotic crosstalk.
    Virology. 2026;620:110913.
    PubMed         Abstract available

  43. SULLIVAN-HILL B, Shahrudin S, Ashley CL, Shields NJ, et al
    SARS-CoV-2 variant-specific enhancement of dendritic heparan sulfate mimetic antiviral activities.
    Virology. 2026;620:110915.
    PubMed         Abstract available

  44. KIMURA R, Hayashi Y, Fujimoto-Sato Y, Ishii H, et al
    Decoding viral evolution through integrative bioinformatics: From genomes to global health.
    Virology. 2026;620:110920.
    PubMed         Abstract available


    Virus Res

  45. WANG X, Guo J, Liu J, Jiang J, et al
    Shared genetic structure between COVID-19 and migraine: insights from large-scale genome-wide cross-trait analysis.
    Virus Res. 2026;367:199708.
    PubMed         Abstract available

  46. NAGHIBOSADAT M, Hahn E, Molinaro S, Babuadze G, et al
    Comparison of SARS-CoV-2 variant pathogenicity in a long-COVID Syrian hamster model.
    Virus Res. 2026;367:199711.
    PubMed         Abstract available

  47. SITHOLE MN, Khan MR, Mohammed HA, Khan RA, et al
    A Systematic Review on Vaccine Developmental Approaches: Evaluating Efficacy, and Addressing Challenges of Infectious Diseases in the Post-COVID-19 Era.
    Virus Res. 2026 Apr 1:199720. doi: 10.1016/j.virusres.2026.199720.
    PubMed         Abstract available

  48. LIU Y, Wang C, Yan D, Zhang Y, et al
    Prognostic prediction in COVID-19 patients: a comprehensive analysis of gut microbiota and hematological biomarkers.
    Virus Res. 2026;367:199729.
    PubMed         Abstract available

Migratory #bird and marine #mammal #surveillance fails to find #evidence for an HPAI #H5N1 2.3.4.4b incursion into #Australia in 2025

 


Abstract

The panzootic caused by high pathogenicity avian influenza (HPAI) H5N1 clade 2.3.4.4b has been devastating for animals, globally. Despite global spread, the virus remains absent in Oceania. Herein we report the results of our fourth year of enhanced migratory bird surveillance, coinciding with the spring migration of wild birds in 2025; none of the 847 migratory wild birds or 38 marine mammals were positive for HPAI H5N1, although we did detect LPAI. Surveillance remains a critical tool for HPAI H5N1 response, with early detection and rapid response being critical to mitigate the impacts of this virus on animal, environment and human health.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

Australian Government Department of Agriculture, Fisheries and Forestry

Wildlife Health Australia

Australian Department of Health, Disability and Ageing

Western Australian Marine Science Institution

Department for Environment and Water, https://ror.org/053gv9453

Department of Climate Change, Energy, the Environment and Water of Australia

Department of Climate Change, Energy, the Environment and Water

Source: 


Link: https://www.biorxiv.org/content/10.64898/2026.05.07.722556v1

____

Variable #transmission efficiency of #mammalian origin #HPAI D1.1 #H5N1 strains in #ferrets

 


Abstract

Highly pathogenic avian influenza H5N1 2.3.4.4b genotype D1.1 lineage continues to predominate in the United States wild bird population and has spilled over into dairy cattle three independent times. To assess the transmission risk of this sublineage, we performed direct-contact transmission experiments for three distinct D1.1 strains in ferrets. Two of these strains were isolated from humans and one from a lethal cat infection. We found that only one human isolate (A/NV/10/2025) was able to transmit efficiently between ferrets. Compared to the other strains, this isolate harbored the mammalian adaptive PB2 D701N mutation, suggesting this mutation may be critical for D1.1 transmission as opposed to the PB2 E627K substitution present in the lethal cat isolate. Based on these data we conclude that the transmission fitness of D1.1 strains is modest but that special attention should be paid to emergence of adaptation at the PB2 701 position.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

National Institute of Allergy and Infectious Diseases, https://ror.org/043z4tv69, 75N93021C00015, 75N93021C00017

Source: 


Link: https://www.biorxiv.org/content/10.64898/2026.05.07.722809v1

____

Friday, May 8, 2026

Evidence of #Juquitiba and #JaborĂ¡ #Orthohantavirus Co-Circulation in #Rodent Communities of #Argentina

 


Abstract

Hantaviruses infect a wide range of vertebrate hosts. In the Americas, Orthohantavirus species pose a major public health concern due to their ability to cause Hantavirus Cardiopulmonary Syndrome (HCPS). Given the lack of approved vaccines and specific treatments for HCPS, identifying circulating orthohantavirus genotypes and their hosts, along with estimating prevalence, is essential for designing effective preventive strategies. The objectives of this study were: (1) to identify the orthohantavirus hosts, (2) to determine the circulating orthohantavirus genotypes, (3) to assess the population structure and dynamics of Akodon montensis, (4) to characterize the rodent communities, and (5) to evaluate associations between A. montensis abundance and environmental variables in two protected natural areas of Misiones Province, Argentina. A total of 12 rodent trapping sessions were conducted from April 2021 to February 2023 in Urugua-Ă­ and Cruce Caballero Provincial Parks. Orthohantavirus antibodies were detected in four A. montensis and three Oligoryzomys nigripes from both Provincial Parks. Molecular analyses provided evidence of the co-circulation of JaborĂ¡ and Juquitiba orthohantavirus genotypes. Both areas exhibited similar rodent community compositions, with A. montensis as the numerically dominant species and O. nigripes occurring at low abundance. In Urugua-Ă­, A. montensis abundance varied in relation to precipitation and vegetation productivity, whereas no such associations were observed in Cruce Caballero. Further studies are needed to effectively monitor these communities and to gain a better understanding of potential fluctuations in seroprevalence, changes in genotype pathogenicity, and the possible detection of unknown genotypes.

Source: 


Link: https://link.springer.com/article/10.1007/s10393-026-01803-8

____

Thursday, May 7, 2026

#Fatal #Human Case of #Influenza #H5N5 in a Backyard Flock Owner — #Washington {State}, November 2025

 


Summary

-- What is already known about this topic?

- Since 2022, highly pathogenic avian influenza (HPAI) A(H5) viruses have circulated among wild birds in the United States. Seventy human cases of influenza A(H5), most with mild illness, have been reported in the United States since 2024; 14 human influenza A(H5N1) cases were previously identified in Washington.

-- What is added by this report?

- In November 2025, Washington reported the first human case of HPAI A(H5N5) infection worldwide. A positive laboratory result was obtained from a lower respiratory sample after multiple negative upper respiratory sample results; the patient experienced respiratory failure and died 28 days after symptom onset. The public health investigation identified approximately 135 exposed persons.

-- What are the implications for public health practice?

- Symptom management and testing of exposed persons are critical to monitoring for human-to-human transmission of novel influenza infection. Environmental and animal investigations, including genomic analysis, can identify epidemiologic risk factors.


Abstract

Clade 2.3.4.4b influenza A(H5N1) viruses have circulated across migratory bird flyways in the United States since 2022, including in Washington, where backyard flock detections have been reported annually. In November 2025, a Washington resident died from acute respiratory failure after receiving a positive influenza A(H5) test result at a hospital laboratory. Washington Public Health Laboratories confirmed influenza A(H5), and genomic sequencing identified influenza A(H5N5) virus (A6 genotype). Polymerase chain reaction testing detected highly pathogenic avian influenza A(H5) virus clade 2.3.4.4b from an apparently healthy backyard flock of ducks and sediment from a watering basin on the patient’s property. Six of eight gene segments from the environmental sample and one duck sample (partial neuraminidase segment) were highly genetically similar to the patient’s virus sequence. Although existing wild bird surveillance had not detected influenza A(H5N5) virus (A6) in the U.S. Pacific Flyway, introduction via wild birds into the environment of the backyard flock was likely the source of the patient’s exposure. The public health investigation identified approximately 135 exposed persons; symptom monitoring and influenza testing detected no additional cases. The overall risk for avian influenza A remains low among the general U.S. population; however, novel avian influenza A virus infection should be considered in persons with symptoms of influenza and potential exposures.

Source: 


Link: https://www.cdc.gov/mmwr/volumes/75/wr/mm7517a2.htm?s_cid=OS_mm7517a2_e&ACSTrackingID=USCDC_921-DM155047&ACSTrackingLabel=Week%20in%20MMWR%3A%20Vol.%2075%2C%20May%207%2C%202026&deliveryName=USCDC_921-DM155047

____

Serologic #Evidence of #Influenza #H5N1 Virus #Infection in a #Veterinary Professional Exposed to an Infected #Cat — Los Angeles County, #California, Dec. '24–Jan. '25

 


Summary

-- What is already known about this topic?

- Transmission of influenza A(H5N1) viruses from domestic cats to humans has not been documented.

-- What is added by this report?

- During November 2024–January 2025, a total of 139 persons exposed to 19 A(H5N1)-infected domestic cats that consumed raw animal products were identified in Los Angeles County, California. Among 25 exposed persons who received serologic testing, one asymptomatic veterinary professional had serologic evidence of A(H5N1) infection after occupational exposure to an A(H5N1)-infected cat.

-- What are the implications for public health practice?

- These findings provide evidence of zoonotic transmission of influenza A(H5N1) virus from domestic cats to humans. Pet owners are advised not to feed raw animal products to cats. Veterinary professionals should be aware of infection risks, use appropriate personal protective equipment, and adhere to recommended infection control practices to reduce the risk for zoonotic transmission of influenza A(H5N1).


Abstract

Since 2021, avian influenza A(H5N1) clade 2.3.4.4b viruses have spread widely among wild birds and domesticated poultry in the United States, with sporadic spillover into mammals. During November 2024–January 2025, 19 domestic cats in Los Angeles County, California, became ill after consumption of commercially purchased raw milk, raw meat, or raw pet food; nine cats tested positive for influenza A(H5N1) virus (clade 2.3.4.4b genotype B3.13). Overall, 139 persons were exposed to the 19 infected cats, and all were monitored for symptoms. Although 30 persons reported influenza-like illness symptoms, none received a positive influenza A(H5) reverse transcription–polymerase chain reaction (RT-PCR) test result. In April 2025, the Los Angeles County Department of Public Health and CDC invited all exposed persons to participate in an influenza A(H5N1) serosurvey to determine whether transmission of influenza A(H5N1) virus occurred, including in those without symptoms. Sera from 25 (18%) of the 139 exposed persons were tested. Among these, antibodies specific to A(H5N1) clade 2.3.4.4.b (antigenically similar to the clade 2.3.4.4.b influenza A[H5N1] virus isolated from the infected cats) were detected in serum from one veterinary professional, who was asymptomatic. This person did not use respiratory or eye protection during the exposure, did not report influenza-like illness after the exposure, and reported no other known risk factors for A(H5N1) infection. These findings represent serologic evidence of possible transmission of influenza A(H5N1) clade 2.3.4.4.b virus from a domestic cat to a human, highlighting concerns about potential cat-to-human transmission of influenza A(H5N1) virus and the importance of infection control practices in veterinary settings.

Source: 


Link: https://www.cdc.gov/mmwr/volumes/75/wr/mm7517a1.htm?s_cid=OS_mm7517a1_e&ACSTrackingID=USCDC_921-DM155047&ACSTrackingLabel=Week%20in%20MMWR%3A%20Vol.%2075%2C%20May%207%2C%202026&deliveryName=USCDC_921-DM155047

____

Immunopathogenic insights into members of the class #Bunyaviricetes: a comparative #review of emerging #zoonotic #threats

 


Abstract

The class Bunyaviricetes encompasses a diverse group of vector- and rodent-borne viruses, many of which are major human pathogens causing severe and often lethal diseases worldwide. These include Lassa fever virus (Arenaviridae), hantaviruses such as Hantaan and Andes viruses (Hantaviridae), Crimean-Congo hemorrhagic fever virus (Nairoviridae), La Crosse and Oropouche viruses (Peribunyaviridae), and Rift Valley fever, severe fever with thrombocytopenia syndrome, and Toscana viruses (Phenuiviridae). Clinical syndromes range from hemorrhagic fever with multiorgan failure, vascular leak, and shock to acute encephalitis and severe respiratory distress. Despite their public health impact, safe and effective vaccines or targeted therapeutics are lacking for most bunyaviricetes diseases, leaving supportive care as the primary intervention. This review provides a comparative analysis of the immunopathogenesis of major human-pathogenic bunyaviricetes, highlighting shared and virus-specific strategies for innate immune evasion, cytokine modulation, and host cell targeting. Severe disease often arises from viral interference with key sensing pathways, such as RIG-I/MDA5 and downstream IRF and NF-κB signaling, which either suppresses interferon responses or leads to dysregulated inflammation. By integrating molecular, immunological, and clinical insights, we outline how these immune-virus interactions shape disease trajectory and severity. Understanding these mechanisms is critical for guiding the rational design of vaccines, antivirals, and immunomodulatory therapies, and for strengthening preparedness against these persistent zoonotic threats.

Source: 

Link: https://www.sciencedirect.com/science/article/pii/S1879625726000362?via%3Dihub

____

Efficacy and #Safety of an #mRNA Seasonal #Influenza #Vaccine in Adults

 


Abstract

Background

Seasonal influenza causes substantial illness and death in adults 50 years of age or older, even with current vaccines. An investigational messenger RNA (mRNA)–based vaccine called mRNA-1010 encodes hemagglutinin glycoproteins from World Health Organization–recommended influenza strains.

Methods

In this phase 3, double-blind, active-controlled trial, we randomly assigned adults 50 years of age or older to receive trivalent mRNA-1010 (37.5 μg, which includes 12.5 μg of each strain) or a licensed standard-dose comparator. The primary efficacy end point was relative vaccine efficacy against reverse-transcriptase–polymerase-chain-reaction (RT-PCR)–confirmed, protocol-defined influenza-like illness caused by influenza A or B, from at least 14 days after vaccination through the end of the influenza season. Hypothesis testing was conducted hierarchically to assess noninferiority (lower boundary of the 95% confidence interval [CI], >−10%), superiority (lower boundary of the 95% CI, >0%), and a higher level of superiority (lower boundary of the 95% CI, >9.1%).

Results

A total of 40,703 participants received mRNA-1010 (20,350 participants) or the standard-dose comparator (20,353 participants); the median follow-up was 181 days (range, 1 to 227). RT-PCR–confirmed, protocol-defined influenza-like illness was observed in 411 of 20,179 recipients of mRNA-1010 (2.0%) and 557 of 20,124 recipients of the standard-dose comparator (2.8%), which corresponds to a relative vaccine efficacy of 26.6% (95% CI, 16.7 to 35.4), thereby meeting the criteria for noninferiority, superiority, and higher-level superiority. Solicited adverse reactions were more frequent with mRNA-1010 than with the standard-dose comparator (injection-site pain in 65.8% vs. 29.8%, fatigue in 45.1% vs. 20.3%, headache in 37.8% vs. 18.0%, and myalgia in 35.4% vs. 11.6%); most reactions were mild to moderate and transient. Serious adverse events were reported in 2.2% of the recipients of mRNA-1010 (with three events considered by the investigator to be vaccine-related) and in 1.9% of the recipients of the standard-dose comparator (with two events considered by the investigator to be vaccine-related).

Conclusions

In this trial, mRNA-1010 was superior to standard-dose licensed vaccines for prevention of RT-PCR–confirmed, protocol-defined influenza-like illness in adults 50 years of age or older. Solicited adverse reactions were more frequent with mRNA-1010. (Funded by Blackstone Life Sciences and Moderna; Fluent ClinicalTrials.gov number, NCT06602024.)

Source: 


Link: https://www.nejm.org/doi/full/10.1056/NEJMoa2516491?query=TOC

____

Wednesday, May 6, 2026

Epidemiological study of #hantavirus in Southern #Brazil, 2009-2019

 


ABSTRACT

Brazil has the highest number of hantavirus cardiopulmonary syndrome cases on the American continent, with Santa Catarina being the state with the most notifications. This retrospective longitudinal study aimed to describe the epidemiological profile of 177 hantavirus cases reported in Santa Catarina from 2009 to 2019, using data from the Notifiable Diseases Information System (SINAN). Statistical analyses of socio-demographic, clinical, and epidemiological data revealed that the typical patient was a male of working age with low educational attainment, living in a rural area. The highest incidence occurred in the Santa Catarina West, Midwest, and Mountain regions, strongly associated with agricultural activities. The case fatality rate (CFR) was highest among the 15-19-year age group. Clinical risk factors for death included respiratory signs, increased hematocrit, and the need for mechanical ventilation. Patients who sought early care had a higher CFR, possibly due to the initial difficulty of differentiating hantavirus from other viral diseases. Conversely, regions with higher notification rates showed lower CFRs, suggesting better surveillance. This study highlights critical areas for public health intervention and the key characteristics of hantavirus patients (males in rural areas and adolescents aged 15-19 years in regions with low notification rates) and areas for public health intervention. Training for medical professionals in regions with low notification rates should aim to reduce lethality, especially in regions with low reported cases (Itajai river delta and South), where underreporting may be occurring. Furthermore, the high lethality in adolescents and in patients with non-specific initial symptoms requires greater awareness. This study shows the utility of a governmental database in identifying epidemiological patterns and creating public health strategies tailored to regional specificities.

Source: 


Link: https://www.scielo.br/j/rimtsp/a/VB7LM8DjmVJ9yJBwYzSjzMh/?lang=en

____

Loss of nsp14-exonuclease activity impairs the #replication, proofreading, fitness, and #pathogenesis of #SARS-CoV-2

 


ABSTRACT

Coronaviruses (CoVs) replicate their RNA genomes with a higher degree of fidelity than other RNA viruses, a mechanism mediated by the proofreading and recombination activities of the exoribonuclease domain of replicase nonstructural protein 14 (nsp14-ExoN). Both murine hepatitis virus (MHV) and SARS-CoV tolerate nsp14-ExoN loss-of-function mutations (ExoN−) (D90A and E92A), but have impaired replication fidelity and pathogenesis; yet identical substitutions in MERS-CoV and SARS-CoV-2 have been reported to be lethal. Here, we report a saturation mutagenesis approach facilitating the recovery and analysis of several constellations of SARS-CoV-2 nsp14 ExoN-inactivating, loss-of-function substitutions, including the canonical D90A and E92A. Biochemical assays with purified WT or ExoN-nsp10-14 fusion proteins confirmed that active site substitutions abolished ExoN activity (ExoN−). SARS-CoV-2 ExoN− viruses exhibited impaired replication, RNA synthesis, and recombination, as well as decreased replication fidelity and loss of fitness in vitro. ExoN− viruses were significantly attenuated for replication in human primary airway epithelial cells and were attenuated for replication and pathogenesis in WT mice, as well as the highly susceptible K18 transgenic mice. In the absence of interferon signaling in vivo, SARS-CoV and SARS-CoV-2 ExoN− viral replication could be partially restored. These results demonstrate that SARS-CoV-2 ExoN− viruses are viable but highly impaired for replication, fitness, and fidelity in vitro, as well as innate immune antagonism and pathogenesis in vivo. Collectively, our results solidify the multiple critical roles of nsp14-ExoN across CoV genera and establish new approaches for rescuing and analyzing loss-of-function substitutions in studies of CoV replication, pathogenesis, and evolution.

Source: 


Link: https://journals.asm.org/doi/10.1128/mbio.00073-26

____

Computational #design of an ultrapotent #deltacoronavirus miniprotein #inhibitor

 


Significance

Multiple porcine deltacoronavirus (PDCoV) spillovers occurred in Haiti and there are currently no vaccines or therapeutics approved for use in humans. We computationally designed PDCoV miniprotein inhibitors and identified one (MB11) that potently and broadly neutralizes distantly related delta-coronaviruses. MB11 is resistant to multiple biochemical stresses, an ideal property for easy storage and delivery. These data pave the way for developing therapeutics to prepare for possible future PDCoV outbreaks.


Abstract

Multiple spillovers of porcine deltacoronavirus (PDCoV) into humans in Haiti highlight its zoonotic potential and the need for targeted interventions. No approved vaccines or therapeutics are available for use in humans against any DCoVs. Here, we report the de novo design of PDCoV miniprotein inhibitors (aka minibinders, MBs) and show that one of them, MB11, binds with picomolar affinity to the PDCoV receptor-binding domain (RBD). MB11 potently inhibits PDCoV, outcompeting monoclonal antibodies, and cross-reacts with and broadly neutralizes a panel of distantly related DCoVs. We determined a cryoelectron microscopy structure of MB11 bound to the PDCoV RBD which reveals the molecular basis of broad DCoV neutralization through interference with host receptor engagement. Deep mutational scanning of the PDCoV RBD reveals that MB11 has a high barrier to viral escape with only few mutations mediating escape without dampening APN receptor binding. MB11 resists stringent biochemical stresses, including high temperature, low pH, and proteolysis, which may enable delivery to various tissues for viral inhibition. This work delineates a prime candidate for clinical evaluation against PDCoV infection and for pandemic preparedness.

Source: 


Link: https://www.pnas.org/doi/abs/10.1073/pnas.2533456123?af=R

____

Disentangling the drivers and host-mediated #global #spread of #H7 #influenza A virus

 


Abstract

Avian influenza H7 viruses pose a significant zoonotic and pandemic threat, yet their evolutionary dynamics, spatial transmission patterns, and host-specific roles remain underexplored. This study integrates phylodynamic and phylogeographic analyses to map global H7 dissemination, quantify host-specific contributions, and identify key ecological and anthropogenic drivers. Epidemiological data show key epidemic waves in Asia during 2013-2014 and 2016-2017, and in Africa in 2023. The Eurasian and American lineages of H7 viruses exhibit transmission with a median velocity of ~661 km/year and ~354 km/year, though spread varies significantly by virus subtype. Anseriformes (~587 km/year) and wild birds (~654 km/year) spread the Eurasian lineage of H7 viruses more rapidly and over greater distances than Galliformes and domestic birds. Geographic distance is negatively associated with the spread of the H7 virus, while temperature and poultry density show positive association. In this work, we identify Asia as an important H7 virus evolutionary epicenter. Anseriformes drives transcontinental spread, whereas Galliformes facilitates local amplification. The dynamics of the H7 virus are shaped by ecological and socioeconomic factors. A One Health approach emphasizing targeted surveillance and global cooperation is essential to mitigate cross-species transmission and future pandemic threats.

Source: 


Link: https://www.nature.com/articles/s41467-026-72718-9

____

Opposing #cell type preferences for binding and #replication shape #influenza A virus infection in #human #airways

 


Abstract

Influenza A viruses (IAVs) pose a persistent threat to human health through seasonal epidemics and zoonotic spillover from avian reservoirs. As respiratory pathogens, they primarily target the airway epithelium. However, it remains unclear how host cell-specific barriers jointly shape viral tropism and replication in primary human airway cultures. Here, we show that avian IAVs can infect ciliated and secretory cells but preferentially bind to ciliated cells, consistent with higher abundance of their receptor alpha2,3-linked sialic acids, specifically sialyl Lewis X glycans, present on the apical surface of ciliated cells. Replication levels were comparable between secretory and ciliated cells for the avian strains, resulting in an overall preference for ciliated cells. In contrast, human IAVs also preferentially bind to ciliated cells but independently of alpha2,6-linked sialic acid abundance. Human IAVs replicate more efficiently than avian IAVs due to their ability to utilize human ANP32 proteins, but they also exhibit cell type-specific differences due to ANP32, allowing for higher viral RNA levels in secretory cells. Thus, preferential binding to ciliated cells coupled with enhanced replication in secretory cells equalizes overall infection levels across cell types for human IAVs. Together, our findings highlight the spatiotemporal complexity and interplay of IAV infection dynamics in the airway epithelium and redefine current models of influenza A virus tropism.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

Swiss National Science Foundation, 310030_204166

UZH Candoc, FK-25-039

Source: 


Link: https://www.biorxiv.org/content/10.64898/2026.05.04.722582v1

____

Tuesday, May 5, 2026

#Surveillance on #California dairy #farms reveals multiple possible sources of #H5N1 #influenza virus #transmission

 


Abstract

Transmission routes of highly pathogenic H5N1 between cows or to humans remain unclear due to limited data from affected dairy farms. We performed air, farm wastewater, and milk sampling on 14 H5N1-positive dairy farms across two different California regions. Infectious virus was detected in the air in milking parlors and in wastewater streams, while viral RNA was found in exhaled breath of cows. Sequence analysis of infectious H5N1 virus from air and wastewater samples on one farm revealed viral variants relevant for potential human susceptibility. Longitudinal analysis of milk from the individual quarters of cows revealed a high prevalence of subclinical H5N1-positive cows. Additionally, a heterogeneous distribution of infected quarters that maintained a consistent pattern over time was observed, inconsistent with shared milking equipment serving as the sole transmission mode. The presence of subclinically infected cows was further supported by detection of antibodies in the milk of animals that exhibited no clinical signs during the H5N1 outbreak on one farm. Our data highlight additional sources and potential modes of H5N1 transmission on dairy farms.

Source: 


Link: https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3003761

____

Respiratory #infections due to #human common cold #coronaviruses, #SARS-CoV, #MERS-CoV, and SARS-CoV-2: #epidemiology, #pathogenesis, clinical features, diagnostics, therapeutics, and vaccine landscapes

 


Summary

Over the past half-century, perceptions of human coronaviruses have evolved from their initial characterisation as causes of the common cold to recognition of their capacity to trigger severe disease and global epidemics. The emergence of three zoonotic coronaviruses—severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002, Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, and SARS-CoV-2 in 2019, has had profound health, economic, and societal consequences and continues to influence global epidemic-preparedness strategies. All three viruses remain on the WHO Blueprint of priority pathogens for research and development. This Review summarises current knowledge on human coronaviruses, drawing lessons from the past 25 years of epidemic outbreaks. The shared and divergent features of SARS-CoV, MERS-CoV, and SARS-CoV-2, including their origins, evolution, transmission determinants, zoonotic transmission, viral entry pathways, pathogenesis, spectrum of clinical manifestations, long-term sequelae, and case-fatality profiles are highlighted. The full range of clinical manifestations, from asymptomatic or atypical presentations to severe acute respiratory and multisystem disease, are outlined together with risk factors for progression and populations with the greatest susceptibility. Diagnostic approaches, including molecular assays, antigen-based tests, and imaging modalities are described alongside current therapeutics, antiviral strategies, immunomodulators, supportive care principles, and evidence from clinical trials. Advances in diagnostics, vaccines, therapeutics, and infection-control practices are examined together with persistent challenges in early recognition, particularly in resource-limited settings. Strengthening multinational clinical trial capacity, leveraging digital innovations, and embedding One Health approaches are essential to mitigating spillover risks and improving global readiness. We review the latest data, identify gaps and opportunities, and outline forward-looking strategies to anticipate and prepare for the threat of future coronaviruses, and other existing or new respiratory pathogens with epidemic potential. Clinicians and other health-care workers play a central role in detecting and reporting possible lethal coronavirus infection including atypical presentations, enabling rapid, coordinated infection control and management responses.

Source: 


Link: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00049-4/abstract?rss=yes

____

Monday, May 4, 2026

Characterization of atypical #Ebola virus disease in #ferrets

 


Abstract

Ebola virus (EBOV) infection typically results in severe—and often lethal—acute disease. However, increasing evidence suggests that EBOV can persist in certain immune-privileged tissues, which may then serve as reservoirs for the later reemergence of EBOV and disease recrudescence. Here, we report atypical EVD recrudescence in a ferret model inoculated with an otherwise lethal dose of EBOV and treated with low doses of a highly potent monoclonal antibody cocktail. Among 32 antibody-treated ferrets, 14 animals survived, while 8 succumbed to acute EVD within about 5–8 days. The remaining 10 animals succumbed to atypical EVD between 12 and 18 days post-infection (DPI) despite having shown no, or very minor, signs of illness during the acute phase of disease. While viremia disappeared by 14 DPI in most animals that succumbed to atypical EVD, it rebounded modestly just prior to death. Unlike animals that died of acute EVD, those that died of atypical EVD showed only a moderate systemic inflammatory response and few signs of organ dysfunction, in line with low levels of virus in the liver and spleen. Interestingly, however, ferrets that died of atypical EVD showed high levels of virus in the brain, consistent with increased markers of inflammation in the central nervous system and significant pathological changes, including a breakdown in the blood-brain barrier and severe meningoencephalitis. Not only does this study shed important light on the atypical and underappreciated manifestations of EVD, but it also establishes the ferret as a valuable model of EBOV recrudescence.

Source: 


Link: https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1013916

____

My New Space

Most Popular Posts